Clinical trials: pMN
Non-Hodgkin's Lymphoma
Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)
The purpose of this trial is to investigate the clinical benefit of the dose intensified regimen, Bi-CHOP in comparison to standard CHOP for advanced intermediate or high grade non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00133302
- Testing
- Standard CHOP, Bi-CHOP (dose intensified CHOP)
- Where
- Japan
- Volunteers
- 450 people
- Sponsor
- Japan Clinical Oncology Group
Chromosome Aberrations
Study on the Impact of Stem Cell Donation and Bone Marrow Harvesting on Unrelated Donors
Granulocyte Colony Stimulating Factor (GCSF) is used extensively as a means of mobilising donor peripheral blood stem cells as an alternative to bone marrow harvesting for the purpose of recipient stem cell transplantation.
- Trial name
- NCT01884610
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University College, London
Myelodysplastic Syndrome, Aplastic Anemia
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
The goal of this clinical research study is to learn if combining the drugs thymoglobulin, methylprednisolone, cyclosporine, and G-CSF (NeupogenTM or NeulastaTM ) can help to control severe aplastic anemia (AA) or hypoplastic…
- Trial name
- NCT00806598
- Testing
- Thymoglobulin, Cyclosporine, Methylprednisolone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Fertility Disorders
Use of Gcsf in Patients With Recurrent Ivf/Icsi Failure
Evaluate the effectiveness of granulocyte colony-stimulating factor (GCSF) in the treatment of thin endometrium or in women with recurrent implantation failure in ICSI cycles
- Trial name
- NCT03023774
- Testing
- Neupogen
- Volunteers
- 20 people
- Sponsor
- Ain Shams Maternity Hospital
Ulcerative Colitis
ADAPT Adacolumn Pediatric Trial in Ulcerative Colitis
Children aged up to 18 years with moderately active Ulcerative Colitis (PUCAI:35-64) will receive one weekly Adacolumn® apheresis treatment over 5 consecutive weeks, followed by up to 3 optional Adacolumn® apheresis treatments…
- Trial name
- NCT00781638
- Testing
- Adacolumn®
- Volunteers
- 24 people
- Sponsor
- Otsuka Frankfurt Research Institute GmbH
Neuroblastoma
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and…
- Trial name
- NCT03363373
- Testing
- GM-CSF + Naxitamab
- Where
- 20 sites in United States, Canada and 7 more
- Volunteers
- 122 people
- Sponsor
- Y-mAbs Therapeutics
Lymphoma, Leukemia
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
The goal of this clinical research study is to find out if giving a boost of natural killer (NK) cells from a donor combined with Rituxan (rituximab), can help to control disease in patients who have already received an…
- Conditions
- Lymphoma, Leukemia, Transplantation, Stem Cell, Lymphoid Malignancies
- Trial name
- NCT00383994
- Testing
- GM-CSF, Rituximab, NK Cell Infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)
The purpose of this study is: 1. To compare priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) during induction and consolidation courses versus no priming. 2.
- Trial name
- NCT00880243
- Testing
- GM-CSF
- Volunteers
- 473 people
- Sponsor
- Acute Leukemia French Association
Neonatal Sepsis
Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates
The investigators aimed to evaluate the effect of G-CSF administration in septic neonates on neutrophil production and CD11b expression.
- Trial name
- NCT01479114
- Testing
- rh-GCSF
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Lymphoma, Leukemia
Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies
The incidence of infectious complications in hematological malignancies is higher than that in children with solid tumors, which may be related to the type and dose intensity of chemotherapy regimens used in hematological tumors.
- Trial name
- NCT04497701
- Testing
- PEG-rhG-CSF group, rhG-CSF group
- Where
- China
- Volunteers
- 139 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Breast Neoplasms, Neoplasm Metastasis
Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer
This is a phase I study to determine the maximal tolerated dose of IL-3 given alone or sequentially with GM-CSF following FLAC chemotherapy in metastatic breast cancer patients.
- Trial name
- NCT00001269
- Testing
- IL-3
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Ulcerative Colitis
Granulocyte-monocyte Apheresis in Ulcerative Colitis
BACKGROUND: Granulocyte-monocyte apheresis has been proposed for the treatment of ulcerative colitis, although is limited by costs and variability of results.
- Trial name
- NCT03189888
- Testing
- apheresis
- Volunteers
- 33 people
- Sponsor
- Valduce Hospital
Bone Pain
Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of…
- Trial name
- NCT03883386
- Testing
- Loratadine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan
Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
The purpose of this study is to learn if a vaccine made from the patient's own tumor cells, then genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), will delay or stop the growth of the…
- Conditions
- Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT00258687
- Testing
- GVAX
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Diabetes Mellitus, Type 1
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects…
- Trial name
- ATG-GCSF (NCT02215200)
- Testing
- Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF)
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary Refractory Neuroblastoma
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
This is a multicenter, randomized, controlled, open-label study. Patients meeting inclusion/exclusion criteria will be randomized (1:1) to receive two cycles of MAb-3F8 plus GM-CSF or RA plus GM-CSF.
- Trial name
- NCT00969722
- Testing
- MAb-3F8, Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), 13-cis-Retinoic Acid
- Where
- 15 sites in United States
- Volunteers
- 1 people
- Sponsor
- United Therapeutics
Leukemia
New Therapy for Advanced Stage Leukemia After Stem Cell Transplantation
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia, particularly for patients with advanced-stage leukemia.
- Trial name
- NCT01455272
- Testing
- prophylactic GPBPCI
- Where
- 6 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Melanoma (Skin)
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Interleukin-2 and sargramostim may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: This phase II trial is studying how well giving interleukin-2 together with sargramostim works in treating…
- Trial name
- NCT00085579
- Testing
- aldesleukin, sargramostim, adjuvant therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute on Chronic Liver Failure
Granulocyte Colony Stimulating Factor(G-CSF) Therapy for Patients With ACLF
The purpose of the study is to determine whether Granulocyte Colony Stimulating factor(G-CSF) therapy is effective in the treatment of patients with Acute on chronic liver failure(ACLF).
- Trial name
- NCT01036932
- Testing
- Granulocyte Colony Stimulating Factor, Normal Saline
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Govind Ballabh Pant Hospital
Leukemia
Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia
RATIONALE: Biological therapy may increase the number of immune cells found in bone marrow and may help a person's immune system recover from the side effects of the chemotherapy used in treating chronic myeloid leukemia.
- Trial name
- NCT00011934
- Testing
- recombinant interferon alfa, sargramostim, autologous bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins